Skip to main content

Table 2 Multivariable overall survival (OS) analysis between SBRT+ADT versus EBRT+ADT (referent) in overall cohort and select subgroups for unfavorable intermediate (a) and high (b) risk prostate cancer

From: Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer

  HR 95% CI p
a. Unfavorable Intermediate Risk
 Overall 1.09 0.68–1.74 .72
Subgroup Analyses
  Excluding any SBRT < 7 Gy per fraction 1.15 0.72–1.83 .57
  Excluding any EBRT < 2 Gy per fraction and < 74 Gy total dose 1.24 0.79–1.96 .35
  Excluding Charlson Deyo ≥1 1.29 0.89–1.34 .33
  Excluding age ≥ 65 1.13 0.86–1.36 .60
b. High Risk
 Overall 0.93 0.76–1.14 .51
Subgroup Analyses
  Excluding SBRT if < 7 Gy per fraction 0.92 0.74–1.14 .44
  Excluding EBRT if < 2 Gy per fraction and < 74 Gy total dose 0.90 0.74–1.10 .30
  Excluding Charlson Deyo ≥1 0.83 0.66–1.03 .10
  Excluding age ≥ 65 0.72 0.44–1.17 .18